The invention relates to a pharmaceutically acceptable carrier that comprises a microRNA selected from the group consisting of miR-15a, miR-181b, miR-320c, miR-874 and any combination thereof, for use in the treatment of renal cancer. The pharmaceutically acceptable carrier is preferably an extracellular vesicle (EV) derived from an adult stem cell selected from the group consisting of a mesenchymal stem cell (MSC), a non-oval human liver progenitor cell (HLSC) and an adipose stem cell (ASC).